|
|
|
Monopar Therapeutics Inc. 
|
6.23 -0.1 (-0.02%) |
03-05 16:00 |
Open: |
6.43 |
Pre close: |
6.33 |
Target:
|
14.81
|
High: |
6.496 |
Low: |
5.6713 |
Resistance:
|
12.68
17.01
|
Volume: |
105,618 |
Market Cap: |
71M |
Support:
|
5.67
4.72
|
|
|
|
Technical Analysis |
Moving Averages |
MA(5):
|
6.68
 |
MACD |
MACD(12,26):
|
-0.29  |
MA(20): |
8.07  |
Signal(12,26,9): |
0.03  |
MA(100): |
6.17  |
Stochastic Oscillator |
%K(14,3):
|
5.24  |
MA(250): |
6.66  |
%D(3): |
3.80  |
Average Volume(K) |
3-Month: |
25785
|
52-Week |
High:
|
17.01 |
10-Days: |
8240 |
Low: |
4.28 |
RSI |
RSI(14):
|
36.31  |
Change(%): |
-26.7 |
Financials, Statistics and Valuation |
EPS |
-0.420 |
Return on Equity (ttm) |
-48.7 |
Shares Out. (M) |
11.45 |
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-29.4 |
Shares Float (M) |
6.23 |
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
73.46 |
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
0.68 |
Forward EPS |
0.000 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
28 |
Book Value (p.s.) |
0.500 |
EBITDA (p.s.) |
0.000 |
P/E |
-14.83 |
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
12.46 |
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-4.09 |
P/S |
0.00 |
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-1.58 |
P/CF |
-17.44 |
|
|
|
|
|